Biosimilars On The Horizon: How Much Will FDA Look To The East?
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe's pathway for follow-on biologics has selling points for both brand and generic firms, but FDA will chart its own course - even as it mulls accepting European data.
You may also be interested in...
Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.
Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.
Biosimilar Guidance: Brands Try Again For A Pre-Approval Requirement
Trade associations representing largely brand manufacturers in the U.S. and Europe want FDA to release guidance on biosimilars before approving any applications, even though the law was written so the agency does not have to wait for guidance to conduct reviews.